| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| 电话： | 800-533-1710 |
| 国际的: | +1 855-379-3115 |
| Values are valid only on day of printing | |
测试ID：OPATX
Opiates Confirmation, Chain of Custody, Random, Urine
Useful For
Suggests clinical disorders or settings where the test may be helpful
Suggests clinical disorders or settings where the test may be helpful
检测和量化可待因, hydrocodone, oxycodone, morphine, hydromorphone, oxymorphone, noroxycodone, noroxymorphone, norhydrocodone, dihydrocodeine, and naloxone在尿液中
每当可以在法院使用测试结果时，就需要监护链。其目的是通过证明其始终涉及对标本的人员的控制来保护贡献标本的个人权利；这种控制表明，篡改标本的机会将受到限制。
Additional Tests
Lists tests that are always performed, at an additional charge, with the initial tests.
Lists tests that are always performed, at an additional charge, with the initial tests.
| 测试ID | Reporting Name | Available Separately | Always Performed |
|---|---|---|---|
| COCH | Chain of Custody Processing | No | 是的 |
| ADLTX | COC，U的掺假剂调查 | 是的 | 是的 |
测试算法
描述将测试添加到初始顺序时的情况。这包括反射和其他测试。
描述将测试添加到初始顺序时的情况。这包括反射和其他测试。
根据调节要求，将对所有监管尿液样品进行掺假剂测试。
方法名称
对执行测试的方法的简短描述
对执行测试的方法的简短描述
免疫测定后，然后进行液相色谱串联质谱法（LC-MS/MS）
纽约州可用
指示纽约州批准的状态以及纽约州客户的测试是否可订购。
指示纽约州批准的状态以及纽约州客户的测试是否可订购。
是的
Reporting Name
列出了测试的已发布名称的缩写或缩写版本
列出了测试的已发布名称的缩写或缩写版本
Opiate Confirmation, CoC, U
Aliases
列出测试的其他通用名称，以帮助搜索
列出测试的其他通用名称，以帮助搜索
Codeine
Dilaudid（Hydomorphone）
Heroin (as Morphine)
Hycodan (Hydrocodone)
氢可酮(Hycodan, Vicodin)
Hydromorphone (Dilaudid, Vicodin)
Lortab (Hydromorphone)
Morphine
Opiates
羟考酮（Oxycontin，Percodan）
Oxycontin (Oxycodone)
Percodan (Oxycodone)
Vicodin (Hydrocodone)
Dihydrocodeine（DHC Plus，Panlor DC，Synalgos DC）
DHC Plus（Dihydrocodeine）
纳洛酮（Narcan）
纳尔康（纳洛酮）
Noroxymorphone
Noroxycodone
万勒DC（二氢可可）
Synalgos DC（Dihydrocodeine）
测试算法
描述将测试添加到初始顺序时的情况。这包括反射和其他测试。
描述将测试添加到初始顺序时的情况。这包括反射和其他测试。
根据调节要求，将对所有监管尿液样品进行掺假剂测试。
标本类型
Describes the specimen type validated for testing
Describes the specimen type validated for testing
尿
标本Required
Defines the optimal specimen required to perform the test and the preferred volume to complete testing
Defines the optimal specimen required to perform the test and the preferred volume to complete testing
补给品:监护链套件（T282）
容器/管：Chain-of-custody kit containing the specimen containers, seals, and documentation required.
标本卷：5毫升
收集说明：在提供的容器，密封并提交相关文档中收集尿液标本，以满足顾客测试的法律要求。
附加信息：Submitting less than 5 mL will compromise our ability to perform all necessary testing.
Forms
1.监护链请求包含在监护链套件中（T282）。
2. If not ordering electronically, complete, print, and send a治疗测试请求（T831）带有标本。
标本最小体积
Defines the amount of sample necessary to provide a clinically relevant result as determined by the Testing Laboratory
Defines the amount of sample necessary to provide a clinically relevant result as determined by the Testing Laboratory
2 mL
拒绝
Identifies specimen types and conditions that may cause the specimen to be rejected
Identifies specimen types and conditions that may cause the specimen to be rejected
| Gross hemolysis | OK |
| Gross icterus | OK |
标本稳定性信息
Provides a description of the temperatures required to transport a specimen to the performing laboratory, alternate acceptable temperatures are also included
Provides a description of the temperatures required to transport a specimen to the performing laboratory, alternate acceptable temperatures are also included
| 标本类型 | Temperature | 时间 | Special Container |
|---|---|---|---|
| 尿 | Refrigerated (preferred) | 28天 | |
| 冷冻 | 28天 | ||
| Ambient | 14 days |
Useful For
Suggests clinical disorders or settings where the test may be helpful
Suggests clinical disorders or settings where the test may be helpful
检测和量化可待因, hydrocodone, oxycodone, morphine, hydromorphone, oxymorphone, noroxycodone, noroxymorphone, norhydrocodone, dihydrocodeine, and naloxone在尿液中
每当可以在法院使用测试结果时，就需要监护链。其目的是通过证明其始终涉及对标本的人员的控制来保护贡献标本的个人权利；这种控制表明，篡改标本的机会将受到限制。
测试算法
描述将测试添加到初始顺序时的情况。这包括反射和其他测试。
描述将测试添加到初始顺序时的情况。这包括反射和其他测试。
根据调节要求，将对所有监管尿液样品进行掺假剂测试。
临床信息
讨论与实验室测试有关的生理学，病理生理学和一般临床方面
讨论与实验室测试有关的生理学，病理生理学和一般临床方面
可待因是通过肝代谢转换为吗啡和诺科丁的半衰期为2至4小时的。如果摄入可待因，在最初的24小时内，可待因与吗啡的比率通常超过尿液的1.0。24小时后，该比率可能低于1.0；30小时后，只能检测到吗啡。
吗啡是从罂粟植物获得的一种天然存在的麻醉镇痛药，Papaver somniferum。吗啡是通过肝代谢转化为2至4小时的正态的。尿液中吗啡的存在可能表明2至3天内暴露于吗啡，海洛因或可待因。摄入含有罂粟种子的面包产品也可能导致吗啡在尿液中排泄。如果消耗过多的量，这可能导致摄入后6至12小时的尿液吗啡浓度高达2000 ng/ml。
氢可酮表现出复杂的代谢模式，包括O-二甲基化，N-甲基化和6-酮对6β羟基甲替代谢物的还原。氢酮和非氢可酮都是氢可酮的代谢产物。二氢可碱也是次要代谢物。在存在大约100倍高的羟考酮或氢电话的情况下，还可以发现痕量的氢可酮，因为它可以是这些药物中的药物杂质。氢可酮的存在大于100 ng/mL，表明在试样收集前2至3天内暴露。
Hydromorphone is metabolized primarily in the liver and is excreted primarily as the glucuronidated conjugate, with small amounts of parent drug and minor amounts of 6-hydroxy reduction metabolites. The presence of hydromorphone greater than 100 ng/mL indicates exposure within 2 to 3 days prior to specimen collection. Hydromorphone is also a metabolite of hydrocodone; therefore, the presence of hydromorphone could also indicate exposure to hydrocodone.
Dihydrocodeine是一种通过可待因的氢化制备的半合成性麻醉镇痛药。它也是氢可酮的小型代谢物。它被代谢为二氢吗啡，半衰期为3.4至4.5小时。
羟考酮被代谢为Noroxycodone，oxymorphone及其葡萄糖醛酸酮，主要通过肾脏排出。大于100 ng/mL的羟考酮的存在表明在收集样品前2至3天内暴露于羟考酮。
矛盾is metabolized in the liver to noroxymorphone and excreted via the kidney primarily as the glucuronide conjugates. Oxymorphone is also a metabolite of oxycodone and, therefore, the presence of oxymorphone could also indicate exposure to oxycodone.
纳洛酮是一种合成的麻醉拮抗剂，用于自然或合成阿片类药物引起的阿片类药物抑郁症的部分或完全逆转。它也已被纳入阿片类药物的口服片以阻止滥用。作用的持续时间取决于给药的剂量和途径。成人的半衰期约为30至81分钟。
The detection interval for the opiates is generally 2 to 3 days after last ingestion.
监护链是标本的处置记录，以记录收集，处理和进行分析的每个人。当标本以这种方式提交时，将以应承受定期法院审查的方式进行分析。
参考值
描述参考间隔和其他信息，以解释测试结果。可能会在适当的情况下包括基于年龄和性别的间隔。除非另有指定，否则间隔是梅奥衍生的。如果提供了解释性报告，则参考值字段将陈述。
描述参考间隔和其他信息，以解释测试结果。可能会在适当的情况下包括基于年龄和性别的间隔。除非另有指定，否则间隔是梅奥衍生的。如果提供了解释性报告，则参考值字段将陈述。
消极的
截止浓度：
免疫测定屏幕
300 ng/ml
Liquid chromatography-tandem mass spectroscopy:
Codeine：25 ng/ml
Dihydrocodeine: 25 ng/mL
氢可酮：25 ng/ml
Norhydrocodone: 25 ng/mL
Hydromorphone：25 ng/ml
Oxycodone：25 ng/ml
Noroxycodone：25 ng/ml
矛盾：25 ng/ml
Noroxymorphone: 25 ng/mL
纳洛酮：25 ng/ml
Morphine：25 ng/ml
解释
Provides information to assist in interpretation of the test results
Provides information to assist in interpretation of the test results
This procedure reports the total urine concentration; this is the sum of the unconjugated and conjugated forms of the parent drug.
Cautions
Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances
Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances
该测试检测到与吗啡结构相似的药物。未检测到阿片类药物中的其他药物，例如芬太尼，梅替丁和美沙酮。
临床参考
Recommendations for in-depth reading of a clinical nature
Recommendations for in-depth reading of a clinical nature
1. Gutstein HB，Akil H：阿片类镇痛药。在：Brunton LL，Lazo JS，Parker KL，编辑。古德曼和吉尔曼的治疗方法。第11版。麦格劳 - 希尔；2006：第21章
2. Basest RC：人类中有毒药物和化学物质的处置。第9版。生物医学出版物；2011
3. Hackett LP, Dusci LJ, Ilett KF, Chiswell GM: Optimizing the水解of可待因and morphine glucuronides in urine. TherDrugmonit。2002; 24（5）：652-657
4. Langman LJ，Bechtel LK, Meier BM, Holstege C: Clinical Toxicology. In: Rifai N, Horvath AR, Wittwer CT, eds. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. 6th ed. Elsevier; 2018:832-887
Method Description
描述如何执行测试并提供特定于方法的参考
描述如何执行测试并提供特定于方法的参考
鸦片中存在于患者尿液中，既是尿液，也存在于硫酸盐或葡萄糖醛酸糖偶联物中。标本最初由免疫测定法筛选。鸦片测定法基于通过光传输变化测量的溶液中微粒的动力学相互作用。在没有样品药物的情况下，可溶性药物结合物与抗体结合的微粒结合，导致颗粒聚集体的形成。随着聚集反应在没有样品药物的情况下进行的，吸光度会增加。当尿液样品含有所讨论的药物时，该药物会与用于结合微粒抗体的药物衍生物结合物竞争。与样品药物结合的抗体不再可用以促进颗粒聚集，随后抑制了颗粒晶格的形成。样品药物的存在减少了与样品中药物浓度成比例的吸光度增加。样品药物含量是根据已知的临界药物浓度获得的值确定的。
The NADH formed during the reaction, measured photometrically as a rate of change in absorbance, is directly proportional to the ethyl alcohol concentration.(Package insert: Opiates. Roche Diagnostics; 11/2017)
After screening, enzyme hydrolysis is used to liberate the conjugated drug. Specimens are then centrifuged, diluted, and the analytes are separated by liquid chromatography-tandem mass spectroscopy and analyzed by multiple reaction monitoring.(Unpublished Mayo method)
PDF报告
Indicates whether the report includes an additional document with charts, images or other enriched information
Indicates whether the report includes an additional document with charts, images or other enriched information
No
Day(s) Performed
Outlines the days the test is performed. This field reflects the day that the sample must be in the testing laboratory to begin the testing process and includes any specimen preparation and processing time before the test is performed. Some tests are listed as continuously performed, which means that assays are performed multiple times during the day.
Outlines the days the test is performed. This field reflects the day that the sample must be in the testing laboratory to begin the testing process and includes any specimen preparation and processing time before the test is performed. Some tests are listed as continuously performed, which means that assays are performed multiple times during the day.
Monday through Friday
可用报告
时间间隔（在Mayo Clinic Laboratories接收样品以可用的结果）考虑yabo208到标准的设置日和周末。第一天是结果通常需要的时间。最后一天是它可能需要的时间，考虑到任何必要的重复测试。
时间间隔（在Mayo Clinic Laboratories接收样品以可用的结果）考虑yabo208到标准的设置日和周末。第一天是结果通常需要的时间。最后一天是它可能需要的时间，考虑到任何必要的重复测试。
2至5天
标本Retention Time
Outlines the length of time after testing that a specimen is kept in the laboratory before it is discarded
Outlines the length of time after testing that a specimen is kept in the laboratory before it is discarded
14 days
执行实验室位置
Indicates the location of the laboratory that performs the test
Indicates the location of the laboratory that performs the test
罗切斯特
Fees
几个因素决定了进行测试的费用。请与您的美国或国际区域经理联系，以获取有关建立费用时间表的信息，或了解有关资源以优化测试选择的更多信息。
几个因素决定了进行测试的费用。请与您的美国或国际区域经理联系，以获取有关建立费用时间表的信息，或了解有关资源以优化测试选择的更多信息。
测试分类
提供有关实验室测试套件和试剂的医疗设备分类的信息。测试可能被归类为美国食品药品监督管理局（FDA）和每个制造商说明使用的清除或批准，或者用作未经全面FDA审查和批准的产品，然后被标记为Analyte特定试剂（ASR）产品。
提供有关实验室测试套件和试剂的医疗设备分类的信息。测试可能被归类为美国食品药品监督管理局（FDA）和每个制造商说明使用的清除或批准，或者用作未经全面FDA审查和批准的产品，然后被标记为Analyte特定试剂（ASR）产品。
该测试是开发的，其性能特征由Mayo诊所以与CLIA要求一致的方式确定。该测试尚未得到美国食品药品监督管理局的清除或批准。
CPT代码信息
Provides guidance in determining the appropriate Current Procedural Terminology (CPT) code(s) information for each test or profile. The listed CPT codes reflect Mayo Clinic Laboratories interpretation of CPT coding requirements. It is the responsibility of each laboratory to determine correct CPT codes to use for billing.
CPT codes are provided by the performing laboratory.
Provides guidance in determining the appropriate Current Procedural Terminology (CPT) code(s) information for each test or profile. The listed CPT codes reflect Mayo Clinic Laboratories interpretation of CPT coding requirements. It is the responsibility of each laboratory to determine correct CPT codes to use for billing.
CPT codes are provided by the performing laboratory.
CPT codes are provided by the performing laboratory.
80361
80365
G0480 (if appropriate)
Test Setup Resources
Setup Files
测试设置信息包含测试文件定义详细信息，以支持Mayo Clinic Laboratories和您的实验室信息系统之间的订单和结果接口。yabo208
测试设置信息包含测试文件定义详细信息，以支持Mayo Clinic Laboratories和您的实验室信息系统之间的订单和结果接口。yabo208
样本报告
提供正常和异常样本报告作为报告外观的参考。
提供正常和异常样本报告作为报告外观的参考。
SI样本报告
国际的System (SI) of Unit reports are provided for a limited number of tests. These reports are intended for international account use and are only available through MayoLINK accounts that have been defined to receive them.
国际的System (SI) of Unit reports are provided for a limited number of tests. These reports are intended for international account use and are only available through MayoLINK accounts that have been defined to receive them.